Prevymis 01
Prevymis Pellet
Product Images NDC 0006-5085
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Prevymis (NDC 0006-5085). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Prevymis 02
The text appears to be a graph displaying the Cumulative Rate of Clinically Significant CHY Infection for two groups, Letermanis and Placebo, over a period of 24 weeks post-transplant. The graph shows a significant difference between the two groups with a two-sided p-value of less than 0.0001. There are also numbers indicating the number of subjects at risk for each group.*
Prevymis 03
This is a description of a medication called PREVYMIST. It is packaged as 28 tablets, with one tablet to be taken daily, and each tablet containing 240mg. The medication is a prescription-only drug and is supplied for a 28-day period. There are also some illegible characters and codes provided that are not usable for generating a description.*
Prevymis 04
PREVYMIS™ is a medication that comes in the form of tablets. Each tablet contains 480 mg of letermovir. The recommended dosage for this medication is one tablet per day. A pack of PREVYMIS™ contains 28 tablets which is a 28-day supply. The NDC number for this medication is 0006-3076-02.*
Prevymis 05
Prevymis 06
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
